Viral vaccines and viral vectors used in biotherapeutic applications carry the risk of microbial contamination, which must be addressed.
Anissa Boumlic
Advertisement
Anissa Boumlic, PHD, is associate director EMEA vaccine and viral therapies, MilliporeSigma.
Articles by Anissa Boumlic
Advertisement
Latest Updated Articles
Ensuring Viral Safety of Viral Vaccines and VectorsSeptember 1st 2018
Advertisement
Advertisement
Trending on BioPharm International
1
BioPharm Brief: Gene Therapy Progress, FDA Approval, and $103M Funding
2
FDA Approves Roche’s Enspryng as First At-Home Subcutaneous Treatment for Thyroid Eye Disease
3
Opus Genetics’ OPGx-LCA5 Gene Therapy Shows Sustained Vision Gains Ahead of Phase 3
4
Estuary Biotherapeutics Launches With $103 Million for ADPKD Gene Therapy
5